TCM
ALXO icon

TCG Crossover Management’s ALX Oncology ALXO Stock Holding History

TCG Crossover Management’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.7M Sell
5,655,487
-7,356,362
-57% -$13.2M 0.28% 45
2026
Q1 		$26.1M Buy
+13,011,849
New +$24.8M 0.75% 31

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

TCG Crossover Management's ALXO Position: Q2 2026 in Review

TCG Crossover Management reduced its ALX Oncology (ALXO) stake by 57% in Q2 2026, selling an estimated $13.2M and leaving 5,655,487 shares worth $11.7M. The position accounts for 0.28% of the portfolio, ranked #45.

TCG Crossover Management first reported a position in ALXO in Q1 2026 and has held it in 2 quarters since. The position peaked at $26.1M in Q1 2026. 94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • TCG Crossover Management held 5,655,487 shares of ALX Oncology worth $11.7M as of Q2 2026.
  • TCG Crossover Management sold 7,356,362 ALX Oncology shares in Q2 2026, an estimated $13.2M.
  • ALX Oncology made up 0.28% of TCG Crossover Management's portfolio in Q2 2026, its #45 holding.
  • TCG Crossover Management first reported a position in ALX Oncology in Q1 2026 and has held it in 2 quarters since.
  • TCG Crossover Management's ALX Oncology position peaked at $26.1M in Q1 2026.
  • 94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on TCG Crossover Management's 13F filing for Q2 2026, filed 14 Aug 2026.